294 related articles for article (PubMed ID: 30578441)
1. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
[TBL] [Abstract][Full Text] [Related]
2. The biology of prostate cancer metastases: does oligo differ from polymetastatic?
Sonpavde G
Curr Opin Urol; 2017 Nov; 27(6):542-546. PubMed ID: 28786848
[TBL] [Abstract][Full Text] [Related]
3. Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment.
Pasoglou V; Michoux N; Van Damme J; Van Nieuwenhove S; Halut M; Triqueneaux P; Tombal B; Lecouvet FE
World J Urol; 2019 Dec; 37(12):2585-2595. PubMed ID: 30826887
[TBL] [Abstract][Full Text] [Related]
4. The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer.
Kucharczyk MJ; Gravis G; Niazi T
Eur Urol Focus; 2019 Mar; 5(2):117-118. PubMed ID: 30527643
[TBL] [Abstract][Full Text] [Related]
5. Sec23a mediates miR-200c augmented oligometastatic to polymetastatic progression.
Sun Z; Zhou S; Tang J; Ye T; Li J; Liu D; Zhou J; Wang J; Rosie Xing H
EBioMedicine; 2018 Nov; 37():47-55. PubMed ID: 30301603
[TBL] [Abstract][Full Text] [Related]
6. Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.
Decaestecker K; De Meerleer G; Ameye F; Fonteyne V; Lambert B; Joniau S; Delrue L; Billiet I; Duthoy W; Junius S; Huysse W; Lumen N; Ost P
BMC Cancer; 2014 Sep; 14():671. PubMed ID: 25223986
[TBL] [Abstract][Full Text] [Related]
7. Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery.
Wright CM; Lee DY; Shimunov D; Carmona R; Barsky AR; Sun L; Cohen RB; Bauml JM; Brody RM; Basu D; Rassekh CH; Chalian AA; Newman JG; Rajasekaran K; Weinstein GS; Lukens JN; Lin A; Swisher-McClure S
Oral Oncol; 2021 Oct; 121():105509. PubMed ID: 34474270
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
[TBL] [Abstract][Full Text] [Related]
9. Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer.
Mercier C; Claessens M; De Troyer B; Debacker T; Fransis K; Vandeursen H; Ost P; Dirix P
Front Oncol; 2022; 12():863609. PubMed ID: 35494057
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis.
Franzese C; Di Brina L; D'Agostino G; Franceschini D; Comito T; De Rose F; Tozzi A; Navarria P; Scorsetti M
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2469-2479. PubMed ID: 31444549
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA expression characterizes oligometastasis(es).
Lussier YA; Xing HR; Salama JK; Khodarev NN; Huang Y; Zhang Q; Khan SA; Yang X; Hasselle MD; Darga TE; Malik R; Fan H; Perakis S; Filippo M; Corbin K; Lee Y; Posner MC; Chmura SJ; Hellman S; Weichselbaum RR
PLoS One; 2011; 6(12):e28650. PubMed ID: 22174856
[TBL] [Abstract][Full Text] [Related]
13. Survival, local control, and health-related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study.
Barzilai O; Versteeg AL; Sahgal A; Rhines LD; Bilsky MH; Sciubba DM; Schuster JM; Weber MH; Pal Varga P; Boriani S; Bettegowda C; Fehlings MG; Yamada Y; Clarke MJ; Arnold PM; Gokaslan ZL; Fisher CG; Laufer I; The Ao Spine Knowledge Forum Tumor
Cancer; 2019 Mar; 125(5):770-778. PubMed ID: 30489634
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy of oligometastatic prostate cancer: a systematic review.
Rogowski P; Roach M; Schmidt-Hegemann NS; Trapp C; von Bestenbostel R; Shi R; Buchner A; Stief C; Belka C; Li M
Radiat Oncol; 2021 Mar; 16(1):50. PubMed ID: 33750437
[TBL] [Abstract][Full Text] [Related]
15. Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.
Joice GA; Rowe SP; Pienta KJ; Gorin MA
Curr Opin Urol; 2017 Nov; 27(6):533-541. PubMed ID: 28863016
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
17. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.
Lecouvet FE; Oprea-Lager DE; Liu Y; Ost P; Bidaut L; Collette L; Deroose CM; Goffin K; Herrmann K; Hoekstra OS; Kramer G; Lievens Y; Lopci E; Pasquier D; Petersen LJ; Talbot JN; Zacho H; Tombal B; deSouza NM
Lancet Oncol; 2018 Oct; 19(10):e534-e545. PubMed ID: 30303127
[TBL] [Abstract][Full Text] [Related]
18. Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer.
Xu LM; Cheng C; Kang M; Luo J; Gong LL; Pang QS; Wang J; Yuan ZY; Zhao LJ; Wang P
Sci Rep; 2017 Aug; 7(1):9255. PubMed ID: 28835666
[TBL] [Abstract][Full Text] [Related]
19. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.
Tang C; Sherry AD; Haymaker C; Bathala T; Liu S; Fellman B; Cohen L; Aparicio A; Zurita AJ; Reuben A; Marmonti E; Chun SG; Reddy JP; Ghia A; McGuire S; Efstathiou E; Wang J; Wang J; Pilie P; Kovitz C; Du W; Simiele SJ; Kumar R; Borghero Y; Shi Z; Chapin B; Gomez D; Wistuba I; Corn PG
JAMA Oncol; 2023 Jun; 9(6):825-834. PubMed ID: 37022702
[TBL] [Abstract][Full Text] [Related]
20. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
Bouman-Wammes EW; van Dodewaard-De Jong JM; Dahele M; Cysouw MCF; Hoekstra OS; van Moorselaar RJA; Piet MAH; Verberne HJ; Bins AD; Verheul HMW; Slotman BJ; Oprea-Lager DE; Van den Eertwegh AJM
Clin Genitourin Cancer; 2017 Oct; 15(5):e773-e782. PubMed ID: 28462855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
